TY - JOUR
T1 - Advancements in the pharmaceutical applications of probiotics
T2 - Dosage forms and formulation technology
AU - Baral, Kshitis Chandra
AU - Bajracharya, Rajiv
AU - Lee, Sang Hoon
AU - Han, Hyo Kyung
N1 - Publisher Copyright:
© 2021 Baral et al.
PY - 2021
Y1 - 2021
N2 - Probiotics have demonstrated their high potential to treat and/or prevent various diseases including neurodegenerative disorders, cancers, cardiovascular diseases, and inflammatory diseases. Probiotics are also effective against multidrug-resistant pathogens and help maintain a balanced gut microbiota ecosystem. Accordingly, the global market of probiotics is growing rapidly, and research efforts to develop probiotics into therapeutic adjuvants are gaining momentum. However, because probiotics are living microorganisms, many biological and biopharmaceutical barriers limit their clinical application. Probiotics may lose their activity in the harsh gastric conditions of the stomach or in the presence of bile salts. Moreover, they easily lose their viability under thermal or oxidative stress during their preparation and storage. Therefore, stable formulations of probiotics are required to over-come the various physicochemical, biopharmaceutical, and biological barriers and to max-imize their therapeutic effectiveness and clinical applicability. This review provides an overview of the pharmaceutical applications of probiotics and covers recent formulation approaches to optimize the delivery of probiotics with particular emphasis on various dosage forms and formulation technologies.
AB - Probiotics have demonstrated their high potential to treat and/or prevent various diseases including neurodegenerative disorders, cancers, cardiovascular diseases, and inflammatory diseases. Probiotics are also effective against multidrug-resistant pathogens and help maintain a balanced gut microbiota ecosystem. Accordingly, the global market of probiotics is growing rapidly, and research efforts to develop probiotics into therapeutic adjuvants are gaining momentum. However, because probiotics are living microorganisms, many biological and biopharmaceutical barriers limit their clinical application. Probiotics may lose their activity in the harsh gastric conditions of the stomach or in the presence of bile salts. Moreover, they easily lose their viability under thermal or oxidative stress during their preparation and storage. Therefore, stable formulations of probiotics are required to over-come the various physicochemical, biopharmaceutical, and biological barriers and to max-imize their therapeutic effectiveness and clinical applicability. This review provides an overview of the pharmaceutical applications of probiotics and covers recent formulation approaches to optimize the delivery of probiotics with particular emphasis on various dosage forms and formulation technologies.
KW - Drug delivery system
KW - Formulation
KW - Gut microbiota
KW - Probiotic
KW - Therapeutic adjuvant
UR - http://www.scopus.com/inward/record.url?scp=85119083214&partnerID=8YFLogxK
U2 - 10.2147/IJN.S337427
DO - 10.2147/IJN.S337427
M3 - Review article
C2 - 34795482
AN - SCOPUS:85119083214
SN - 1176-9114
VL - 16
SP - 7535
EP - 7556
JO - International Journal of Nanomedicine
JF - International Journal of Nanomedicine
ER -